Though the trial demonstrates the feasibility of the approach, future research is needed to assess the clinical impact.
Cardio-oncologists should incorporate vascular prevention in their care, especially for those without protective hormones.
The dual approach, though rare, was linked to fewer 2-year MACE and lower long-term costs compared with angiography alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results